Sharemaestro Newsreel

AbbVie to Acquire Apogee Therapeutics for $10.9 Billion; Apogee Reports Positive Phase 2 Zumilokibart Data and Q2 2026 Results

AbbVie plans to acquire Apogee Therapeutics for $10.9 billion, or $135.11 per share, to bolster its immunology portfolio. This acquisition follows Apogee's positive Phase 2 results for zumilokibart in atopic dermatitis and a $1.3 billion financing deal with Blackstone Life Sciences. The deal is …

Apogee's Atopic Dermatitis Drug Shows 65.9% EASI-75

Apogee Therapeutics announced its Q2 2026 financial results and significant corporate updates, including AbbVie's agreement to acquire the company for approximately $10.9 billion. The acquisition, valued at $135.11 per share in cash, is expected to close in Q3 2026. Additionally, Apogee reported positive Phase …

ACCESS Announces Multi-Year Strategic Agreement to Bring Advanced Cardiac Electrophysiology Technologies to Ambulatory Surgery Centers

Agreement supports ACCESS-affiliated ASCs in adopting the CARTO™ System and its integrated portfolio of mapping, intracardiac imaging, radiofrequency ablation and pulsed field ablation technologies NEW YORK, August 10, 2026--(BUSINESS WIRE)--ACCESS, through its physician-led group purchasing organization, ACCESS GPO, today announced a multi-year preferred portfolio …

Veru Reports Fiscal 2026 Third Quarter Financial Results and Phase 2b PLATEAU Clinical Trial Progress

Veru Inc. -- Phase 2b PLATEAU clinical trial of enobosarm and semaglutide combination for high quality weight loss is fully enrolled with 239 patients – -- Phase 2b PLATEAU clinical trial interim analysis and results on track for calendar Q1 2027-- -- In June …

This Insider Has Just Sold Shares In Johnson & Johnson

Johnson & Johnson's CEO & Chairman, Joaquin Duato, recently sold US$13m worth of stock at US$258 per share, representing a 14% decrease in his holding. This follows an earlier sale this year at a lower price of US$221 per share. While the sales are …

Novo’s Catalent plant ditched in FDA refiling of SMA drug

Scholar Rock has removed Novo Nordisk’s legacy Catalent facility as a contract manufacturer for its spinal muscular atrophy drug, apitegromab, in its FDA refiling due to ongoing issues at the plant. This decision follows multiple FDA citations and an "Official Action Indicated" designation for …

Update: Scholar Rock Holding Says Apitegromab BLA Review Stays on Track for September 30 PDUFA Date

(Updates with day of announcement in first paragraph, Novo Nordisk's affiliation in the second paragraph, and latest stock moves in the fourth paragraph.)Scholar Rock Holding (SRRK) said Friday that the FDA review of its apitegromab Biologics License Application for spinal Silver Upgrade to read …

Amgen Inc. (AMGN) Stock Analysis: Navigating a Strong Market Cap with High Return on Equity

Amgen Inc. (AMGN) is a significant player in the healthcare sector with a market capitalization of $221.79 billion. The company boasts a strong financial position, evidenced by its forward P/E ratio of 17.03, a remarkable return on equity of 91.47%, and robust free cash …

AbbVie Inc. (ABBV) Stock Analysis: Evaluating Growth Potential With A 11.51% Upside

AbbVie Inc. (ABBV) is a biopharmaceutical company with a strong market presence, a current stock price of $246.04, and a potential upside of 11.51% according to analyst ratings. While the company boasts significant revenue growth, strong operational efficiency, and an attractive dividend yield, its …

AMGEN INC : HSBC RAISES TARGET PRICE TO $445 FROM $425

HSBC has increased its target price for Amgen Inc. shares to $445, up from the previous $425. This adjustment reflects a positive outlook from the banking giant on the pharmaceutical company's stock.

Storebrand Europe Index - announcement of prospectus

Storebrand Asset Management AS Lysaker, 10 August 2026 Storebrand hereby announces the Prospectus with Articles of Association Appendix to the Prospectus ("tillæg" relevant to Danish investors) for Storebrand Europe Index, an index aware equity fund. The fund has been accepted for listing at Nasdaq …

AbbVie Inc. (NYSE:ABBV) Receives Average Recommendation of "Moderate Buy" from Brokerages

AbbVie Inc. (NYSE:ABBV) has received a "Moderate Buy" consensus rating from 24 brokerages, with an average 12-month price target of $275.70, exceeding its current share price. The company surpassed quarterly earnings expectations with adjusted EPS of $3.65 and revenue of $16.99 billion, marking a …

Astrazeneca Plc $AZN Shares Sold by FNY Investment Advisers LLC

FNY Investment Advisers LLC significantly reduced its stake in AstraZeneca Plc by 97.2% in Q2 2026, selling 7,050 shares and retaining 200. This comes despite AstraZeneca beating EPS estimates with $2.63, though its revenue of $15.38 billion slightly missed forecasts. The stock currently holds …

Erste Group Bank Brokers Lower Earnings Estimates for Amgen

Erste Group Bank has lowered its FY2027 EPS estimate for Amgen to $23.50 from $23.58, while maintaining a "Hold" rating on the stock. This revised estimate still remains above the current full-year consensus of $22.78. Amgen reported strong Q2 results, with EPS of $6.29 …

Weekly Recap: Merger talks with Bristol Myers and Imjudo launch in China

AstraZeneca (AZN) has been involved in preliminary merger discussions with Bristol Myers Squibb, which reportedly led to a dip in AZN's share price. Concurrently, AstraZeneca is focusing on organic growth, marked by the launch of its cancer drug Imjudo in China, a new biologics …

Nvidia, Eli Lilly, and Disney Show It’s Time to Back the Top Dogs

Investors are still skittish enough that they only want to buy proven winners, so backing the favorite is a smart strategy right now. Continue Reading

Pfizer explores localisation, supply-chain and healthcare partnerships across Middle East, Africa

Pfizer is actively seeking manufacturing, technology transfer, research, and capability-building partnerships across the Middle East and Africa. This initiative responds to the region's growing demand for drug security and innovative therapies, driven by demographic growth and increased healthcare investment. The company aims to strengthen …

Dr Reddy’s to discontinue marketing of Novartis in-licensed brands from October

Dr. Reddy's Laboratories will cease marketing select Novartis India brands from October 1, 2026, due to a change in Novartis India's ownership. This decision follows Novartis AG's divestment of its controlling stake in Novartis India to private equity firm ChrysCapital. Dr. Reddy's had an …

Ozempic For $50 a Month? Amazon Pharmacy Rolls Out Cheap Weight-Loss Drugs for Medicare Patients

Benzinga and Yahoo Finance LLC may earn commission or revenue on some items through the links below. Amazon.com Inc.'s Amazon Pharmacy will offer eligible Medicare beneficiaries weight-loss drugs for $50 per month through a new federal program aimed at expanding access. The company announced …

Bristol Myers Squibb Invests $2.3B in New Houston Pharma Facility

Bristol Myers Squibb is investing $2.3 billion to construct a 600,000-square-foot manufacturing facility at Generation Park in northeast Houston, expected to create nearly 500 jobs. This significant investment further establishes Houston as a leading hub for life sciences and advanced manufacturing, following similar large-scale …

The 5 Most Interesting Analyst Questions From AbbVie’s Q2 Earnings Call

The 5 Most Interesting Analyst Questions From AbbVie's Q2 Earnings Call AbbVie's second quarter results reflected robust product performance but were met with cautious investor sentiment. Management credited double-digit sales growth to strong execution in core immunology therapies, especially SKYRIZI and RINVOQ, and notable …

Zimmer Biomet Q2 Earnings Call Highlights

Key Points Interested in Zimmer Biomet Holdings, Inc.? Here are five stocks we like better. Zimmer Biomet reported solid Q2 growth: Net sales rose 4.8% to $2.177 billion, driven by hips, specialty businesses and technology. Adjusted EPS was $2.07, while U.S. organic sales increased …

Gilead Sciences, Inc. Revenue Breakdown – SIX:GILD

Gilead Sciences, Inc. generated 23.34 billion CHF in revenue last year. Its top-performing segment, Human Immunodeficiency Virus, contributed 16.45 billion CHF, a decrease from the previous year. The United States was the largest regional contributor, accounting for 16.55 billion CHF.

Amgen Inc. (AMGN) Stock forecasts

Amgen, a leader in biotechnology, is experiencing broad-based growth despite biosimilar competition for Prolia, leading Morningstar to maintain its fair value assessment. The company's flagship drugs include Epogen, Aranesp, Neupogen, Neulasta, Enbrel, Otezla, and its first cancer therapeutic, Vectibix. The current stock price is …

Johnson & Johnson Has Increased Its Dividend for 64 Consecutive Years. Here's How Much $10,000 Invested in the Dividend King Pays Annually.

Key Points Few companies have a longer track record of uninterrupted dividend growth. This streak is likely to be prolonged well into the foreseeable future. While still an income stock, Johnson & Johnson is also being priced somewhat like a growth stock.10 stocks we …

Notable healthcare headlines for the week: Eli Lilly, Novo Nordisk, and Pfizer in focus

Wall Street’s major market averages ended higher on Friday after July's nonfarm payrolls surprised to the downside, showing an unexpected contraction in employment. The blue-chip Dow edged up 0.3%, the benchmark S&P 500 gained 0.62%, and the tech-focused Nasdaq Composite jumped 1.3%. The S&P …

Top global stories this week: BP, SoftBank among notable names

US stock indexes ended the week higher supported by a rally in mega-cap technology stocks, a rebound in Treasury securities and robust corporate earnings. By the end of the week, geopolitical tensions involving Iran pushed crude oil prices toward $78 per barrel, raising fears …

Eli Lilly (LLY) Posts Blowout Growth And Raises Its Outlook

Eli Lilly (NYSE:LLY) delivered a quarter that forced Wall Street to catch up to its own numbers. On August 5, the company reported second-quarter revenue of $23.0 billion, up 48% from a year earlier, and used the momentum to raise its full-year sales and …

Avity Investment Management Inc. Has $27.59 Million Stock Holdings in Amgen Inc. $AMGN

Avity Investment Management Inc. significantly increased its stake in Amgen Inc. by 5.3% in the second quarter, bringing its total holdings to 76,186 shares valued at approximately $27.59 million. Amgen recently reported strong second-quarter results, exceeding revenue and EPS expectations, and raised its 2026 …

Johnson & Johnson (JNJ) Stock Looks Cheap On Cash Flow Yet Pricey On Earnings

Cardano Risk Management B.V. Sells 14,358 Shares of Amgen Inc. $AMGN

Cardano Risk Management B.V. has reduced its stake in Amgen Inc. by 5.2%, selling 14,358 shares and retaining 260,359 shares valued at $94.3 million. Amgen reported strong Q2 2026 results, exceeding revenue and EPS expectations, and raised its full-year earnings guidance despite discontinuing an …

Amarin Corporation PLC (AMRN) Earnings Forecast: Future EPS & Revenue Growth Estimates

Eli Lilly and Company Q2 Earnings Call Highlights

Eli Lilly and Company reported a 48% year-over-year revenue growth in Q2 2026, driven by strong sales of MOUNJARO and ZEPBOUND, leading the company to raise its full-year revenue and earnings guidance. The demand for obesity medicines remained robust, with prescriptions up 78% year-over-year, …

Should Biogen’s Profit Squeeze Amid Rising New-Therapy Sales Prompt Action From Biogen (BIIB) Investors?

Biogen (BIIB) reported increased revenue in Q2 2026, driven by new therapies and the Apellis acquisition, but experienced a significant drop in net income and diluted EPS. This profit squeeze highlights challenges in offsetting the decline of its legacy multiple sclerosis portfolio with new …

Is Sanofi (ENXTPA:SAN) Cheap Following MenQuadfi Approval For Infants?

Sanofi received European Commission approval to expand the MenQuadfi meningococcal vaccine's use to infants as young as six weeks old, covering a high-risk population. Despite this and a recent share buyback, Sanofi's stock performance has been subdued. The company's valuation narrative suggests it is …

Biotechnology Stocks To Watch As Investors Look Past Pfizer’s Covid Revenue Drop